Myriad Genetics Q3 net loss widens 60% to $43.9 million; revenue falls to $202.7 million
LH•Myriad Genetics reported a third-quarter 2026 net loss of $43.9 million, up 60% year over year, and revenue of $202.7 million, down year over year. It raised its full-year revenue guidance midpoint and agreed to sell Prenatal Health to Labcorp for $210 million plus inventory value.
1. Quarterly results and outlook
Myriad Genetics’ third-quarter 2026 net loss widened 60% year over year to $43.9 million, while revenue fell to $202.7 million. Operating expenses rose 6% to $177.6 million. The company raised the midpoint of its full-year 2026 revenue guidance to a range of $780 million to $790 million, reflecting quarterly results and current trends.
2. Prenatal Health sale
Myriad Genetics agreed to sell Prenatal Health to Labcorp for $210 million plus inventory value. The closing is expected by early 2027.
